# To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

> **NCT06154967** · NA · UNKNOWN · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

## Interventions

- **RADIATION:** tereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT06154967
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06154967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06154967, "To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06154967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*